Basilea Pharmaceutica AG
SIX:BSLN

Watchlist Manager
Basilea Pharmaceutica AG Logo
Basilea Pharmaceutica AG
SIX:BSLN
Watchlist
Price: 54.7 CHF -2.32% Market Closed
Market Cap: CHf663m

Operating Margin

32.2%
Current
Improving
by 12.6%
vs 3-y average of 19.6%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
32.2%
=
Operating Income
CHf76m
/
Revenue
CHf236.2m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
32.2%
=
Operating Income
CHf76m
/
Revenue
CHf236.2m

Peer Comparison

Country Company Market Cap Operating
Margin
CH
Basilea Pharmaceutica AG
SIX:BSLN
673.1m CHF
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
389.3B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.3B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
170.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.4B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.4B USD
Loading...

Market Distribution

Higher than 89% of companies in Switzerland
Percentile
89th
Based on 1 083 companies
89th percentile
32.2%
Low
-62 472.2% — 3.5%
Typical Range
3.5% — 16.5%
High
16.5% — 91.2%
Distribution Statistics
Switzerland
Min -62 472.2%
30th Percentile 3.5%
Median 10.3%
70th Percentile 16.5%
Max 91.2%

Basilea Pharmaceutica AG
Glance View

Market Cap
663m CHF
Industry
Biotechnology

Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Basel, Basel-Stadt and currently employs 154 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. The company launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.

BSLN Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
32.2%
=
Operating Income
CHf76m
/
Revenue
CHf236.2m
What is Basilea Pharmaceutica AG's current Operating Margin?

The current Operating Margin for Basilea Pharmaceutica AG is 32.2%, which is above its 3-year median of 19.6%.

How has Operating Margin changed over time?

Over the last 3 years, Basilea Pharmaceutica AG’s Operating Margin has increased from 4.3% to 32.2%. During this period, it reached a low of -5.7% on Jun 30, 2024 and a high of 37.1% on Jun 30, 2023.

Back to Top